Skip to main content
Figure 3 | BMC Infectious Diseases

Figure 3

From: Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study

Figure 3

Cost-effectiveness acceptability curve of SPRINT-2 treatment strategies. BOC/RGT vs. PR48 and BOC/PR48 vs. PR48. PR48 – peginterferon-ribavirin regimen for 48 weeks; BOC/RGT – peginterferon-ribavirin and boceprevir for 24 weeks, and those with a detectable hepatitis C virus (HCV) RNA level between weeks 8 and 24 received peginterferon–ribavirin from week 28 to week 48; BOC/PR48 –peginterferon–ribavirin for 48 weeks and boceprevir for 44 weeks.

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us